Overview A Safety, Tolerability, Efficacy and Exposure Study of XEN801 Topical Gel Status: Completed Trial end date: 2017-03-17 Target enrollment: Participant gender: Summary Phase 1/2 study enrolling up to 60 healthy volunteers in Phase 1 followed by approximately 150 subjects with acne vulgaris in Phase 2. Phase: Phase 1/Phase 2 Details Lead Sponsor: Xenon Pharmaceuticals Inc.